Emergent BioSolutions Inc (EBS)

34.66
0.01 0.03
NYSE : Health Care
Prev Close 34.65
Open 34.86
Day Low/High 34.22 / 34.90
52 Wk Low/High 24.47 / 36.64
Volume 98.62K
Avg Volume 315.10K
Exchange NYSE
Shares Outstanding 40.97M
Market Cap 1.39B
EPS 1.30
P/E Ratio 25.91
Div & Yield N.A. (N.A)

Latest News

Emergent BioSolutions To Unveil Its Expanded Center For Innovation In Advanced Development And Manufacturing Supported Through Public-Private Partnership With BARDA

112,000-Square-Foot Baltimore Facility Is Designed to Enable Surge Manufacturing of Medical Countermeasures to Address Urgent Public Health Threats

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Emergent Biosolutions Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 19, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Emergent Biosolutions Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 19, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc.

EBS SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Emergent Biosolutions Inc. And A Lead Plaintiff Deadline Of September 19, 2016

EBS SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Emergent Biosolutions Inc. And A Lead Plaintiff Deadline Of September 19, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Maryland on behalf of investors who purchased Emergent Biosolutions Inc.

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Emergent BioSolutions, Inc. Investors And Encourages Investors To Contact The Firm

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Emergent BioSolutions, Inc. Investors And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Emergent BioSolutions, Inc.